Antitumor activity of gel-forming preparation prospidin on the model of Zaidela ascitic hepatoma

Abstract

Using a model of transplanted Zaidela ascitic hepatoma, the antitumor activity of hydrogel of dextran phosphate (DP) was assessed for both gel-forming and injectional prospidin forms. The drug prospidin, in injectional form and in the form of hydrogels (at doses 250, 500, 750, and 1000 mg/kg), as well as dextran phosphate hydrogel (at doses of 500 and 1000 mg/kg), was administered once intraperitoneally (in a volume of 1 or 2 mL/100 g of animal body). The studies performed have shown that all medicinal forms produce inhibition of the increment of body mass in rats with Zaidela ascitic hepatoma, as well as a significant increase in their mean lifespan. The antitumor effect of all drugs is dose-dependent; i.e., with an increase in the doses of the medicinal forms of prospidin and DP hydrogel, the mean rat lifespan increases. The gel-forming prospidin form provides a more than twofold increase in the effect of antitumor activity as compared with the injectional form and prolongation of therapeutic action, as well as curing of animals in more than 60% of cases.